Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$1.76
+1.4%
$1.72
$1.41
$5.01
$9.71M1.1822,210 shs10,942 shs
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
$4.51
+3.6%
$3.59
$1.00
$5.87
$39.95M0.65142,792 shs5,313 shs
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
$0.77
-0.1%
$0.97
$0.76
$13.59
$29.54M-0.25300,539 shs41,277 shs
Scilex Holding stock logo
SCLX
Scilex
$5.62
+7.0%
$6.20
$3.60
$80.50
$39.07M1.183,889 shs48,509 shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
+0.58%+8.12%-1.14%-30.80%-65.19%
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
+1.64%+8.48%+25.00%+12.40%+123.08%
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
-4.82%-15.39%-31.90%-35.05%-93.55%
Scilex Holding stock logo
SCLX
Scilex
+8.25%+10.76%+6.06%-34.21%-86.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.4818 of 5 stars
3.54.00.00.03.22.51.3
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
1.9047 of 5 stars
3.33.00.00.02.41.70.0
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
2.5046 of 5 stars
3.62.00.00.02.62.50.6
Scilex Holding stock logo
SCLX
Scilex
2.3326 of 5 stars
3.33.00.00.02.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.00
Buy$15.50783.19% Upside
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
2.50
Moderate Buy$12.00166.37% Upside
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
3.20
Buy$13.001,583.94% Upside
Scilex Holding stock logo
SCLX
Scilex
2.60
Moderate Buy$455.007,996.09% Upside

Current Analyst Ratings Breakdown

Latest APRE, FBLG, ATHE, and SCLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/11/2025
Scilex Holding stock logo
SCLX
Scilex
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/11/2025
Scilex Holding stock logo
SCLX
Scilex
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/9/2025
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/2/2025
Scilex Holding stock logo
SCLX
Scilex
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$770.00 ➝ $630.00
4/1/2025
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/1/2025
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/25/2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
2/28/2025
Scilex Holding stock logo
SCLX
Scilex
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$770.00 ➝ $770.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$580K16.74N/AN/A$4.54 per share0.39
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/A$1.04 per shareN/A
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/A$0.04 per shareN/A
Scilex Holding stock logo
SCLX
Scilex
$50.71M0.77N/AN/A($1.10) per share-5.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$14.29M-$2.37N/AN/AN/A-1,029.50%-57.86%-47.94%8/11/2025 (Estimated)
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
-$12.54MN/A0.00N/AN/AN/AN/A8/4/2025 (Estimated)
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
-$16.49M-$0.21N/AN/AN/AN/AN/A-225.34%8/6/2025 (Estimated)
Scilex Holding stock logo
SCLX
Scilex
-$114.33M-$29.02N/AN/AN/A-159.10%N/A-93.65%8/12/2025 (Estimated)

Latest APRE, FBLG, ATHE, and SCLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million
5/13/2025Q1 2025
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
-$0.10-$0.14-$0.04-$0.14N/AN/A
3/31/2025Q4 2024
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
-$0.10-$0.09+$0.01-$0.09N/AN/A
3/25/2025Q4 2024
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.69-$0.49+$0.20-$0.49$0.15 million$0.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/AN/A
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/AN/A
Scilex Holding stock logo
SCLX
Scilex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
7.28
7.28
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
N/A
3.54
3.54
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
N/A
1.23
1.23
Scilex Holding stock logo
SCLX
Scilex
N/A
0.14
0.13

Institutional Ownership

CompanyInstitutional Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
2.14%
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
N/A
Scilex Holding stock logo
SCLX
Scilex
69.67%

Insider Ownership

CompanyInsider Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
12.80%
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
38.80%
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
20.00%
Scilex Holding stock logo
SCLX
Scilex
7.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
75.53 million4.74 millionNo Data
Alterity Therapeutics Limited stock logo
ATHE
Alterity Therapeutics
108.87 million5.35 millionNot Optionable
FibroBiologics, Inc. stock logo
FBLG
FibroBiologics
1038.26 million28.84 millionN/A
Scilex Holding stock logo
SCLX
Scilex
806.95 million222.07 millionOptionable

Recent News About These Companies

Scilex treatment of pericarditis granted FDA orphan designation
Scilex confirms FDA awards orphan drug designation for colchicine
Scilex announces 1-for-35 reverse stock split
Scilex regains compliance with Nasdaq listing rules

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$1.76 +0.03 (+1.45%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Alterity Therapeutics stock logo

Alterity Therapeutics NASDAQ:ATHE

$4.50 +0.16 (+3.56%)
As of 11:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

FibroBiologics stock logo

FibroBiologics NASDAQ:FBLG

$0.77 0.00 (-0.12%)
As of 11:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Scilex stock logo

Scilex NASDAQ:SCLX

$5.62 +0.37 (+7.05%)
As of 11:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.